142896-15-9

Basic information

• Product Name: 4-Pyridinecarboxylic acid, 2,6-dimethyl-, methyl ester
• Synonyms: Methyl 2,6-dimethylpyridine-4-carboxylate
• CAS NO: 142896-15-9
• Molecular Formula: C9H11NO2
• Molecular Weight: 165.19
• Mol File: 142896-15-9.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-Pyridinecarboxylic acid, 2,6-dimethyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridinecarboxylic acid, 2,6-dimethyl-, methyl ester(142896-15-9)
• EPA Substance Registry System: 4-Pyridinecarboxylic acid, 2,6-dimethyl-, methyl ester(142896-15-9)

Safety Data

• Hazardous Substances Data: 142896-15-9(Hazardous Substances Data)

Usage

General Description

4-Pyridinecarboxylic acid, 2,6-dimethyl-, methyl ester is a chemical compound that has various industrial and pharmaceutical applications. It is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and dyes. This chemical is also used as a flavoring agent, as well as an intermediate in the production of perfumes and other aromatic compounds. Additionally, it has potential applications in the production of polymers and adhesives. 4-Pyridinecarboxylic acid, 2,6-dimethyl-, methyl ester is considered to be relatively stable and has low toxicity, making it suitable for use in a wide range of industrial processes.

Upstream product

• 108-75-8 2,4,6-trimethyl-pyridine 
• 18206-06-9 2,6-dimethyl-4-pyridine carboxaldehyde 
• 186581-53-3 diazomethane 
• 54221-93-1 2,6-dimethylisonicotinic acid 
• 1122-43-6 2,6-dimethyl-3-hydroxypyridine 
• 42521-09-5 methyl 2,6-dichloroisonicotinate 
• 544-97-8 dimethyl zinc(II) 
• 113708-04-6 2,6-dimethylpyridine-4-carboxamide 
• 67-56-1 methanol 

Relevant articles and documents

KINASE ANTAGONISTS AND METHODS FOR MAKING AND USING THEM

Disclosed herein are small molecule compounds that are SGK1 antagonists, formulations and pharmaceutical compositions comprising the compounds, and methods of making and using them, for treating, ameliorating, preventing, reversing or slowing the progression of: a cancer, a tumor, a metastasis or a dysplastic or a dysfunctional cell condition responsive to inhibition of a kinase enzyme of the AGC group of kinases including SGK1, by administration of an AGC kinase inhibitor or antagonist.

Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors

The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

Sulfone-mediated synthesis of polysubstituted pyridines

Base-mediated and/or palladium(0)-catalysed bis(allylation) of alkyl 2-(tolylsulfonyl)acetates gives 1,6-dienes, which upon ozonolytic cleavage of the double bonds and ammonolysis give 2,6-disubstituted pyridine-4-carboxylic esters. Decarboxylation of one